0000902664-24-004124.txt : 20240607
0000902664-24-004124.hdr.sgml : 20240607
20240607163117
ACCESSION NUMBER: 0000902664-24-004124
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yi Qingqing
CENTRAL INDEX KEY: 0001662556
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37686
FILM NUMBER: 241030073
MAIL ADDRESS:
STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES
STREET 2: 94 SOLARIS AVENUE
CITY: CAMANA BAY, GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BeiGene, Ltd.
CENTRAL INDEX KEY: 0001651308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981209416
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
STREET 2: 94 SOLARIS AVENUE, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
BUSINESS PHONE: 13459494123
MAIL ADDRESS:
STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
STREET 2: 94 SOLARIS AVENUE, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
4
1
ownership.xml
X0508
4
2024-06-05
0
0001651308
BeiGene, Ltd.
BGNE
0001662556
Yi Qingqing
OFFICE #122, WINDWARD 3 BUILDING
REGATTA OFFICE PARK
GEORGE TOWN, GRAND CAYMAN
E9
KY1 1103
CAYMAN ISLANDS
1
0
0
0
0
Ordinary Shares
2024-06-05
4
A
0
16341
0
A
45955
D
Share Option (Right to Buy)
12.23
2024-06-05
4
A
0
34151
0
A
2034-06-04
Ordinary Shares
34151
34151
D
Represents securities underlying restricted share units ("RSUs"). All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares.
The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
/s/ Qingqing Yi
2024-06-07